臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 52962981 在线人数 : 1407 教育部委托研究计画计画执行:国立台湾大学图书馆

搜寻范围

进阶搜寻

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"hsu c h"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 326-335 / 1656 (共166页)
<< < 28 29 30 31 32 33 34 35 36 37 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2021-08-31T06:29:24Z	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment	Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2021-08-31T06:29:23Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:22Z	Potent activity of composite cyclin dependent kinase inhibition against hepatocellular carcinoma	Shao Y.-Y.; Li Y.-S.; Hsu H.-W.; Lin H.; Wang H.-Y.; Wo R.R.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2021-08-31T06:29:21Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2021-08-31T06:29:21Z	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:19Z	A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors	Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; ANN-LII CHENG; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C.
臺大學術典藏	2021-08-31T06:29:18Z	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO	Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y.
臺大學術典藏	2021-08-31T06:29:18Z	Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours	de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:15Z	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy	Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏	2021-08-31T06:29:13Z	An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma	Shao Y.-Y.; ANN-LII CHENG; Hsu C.-H.

显示项目 326-335 / 1656 (共166页)
<< < 28 29 30 31 32 33 34 35 36 37 > >>
每页显示[10|25|50]项目